• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Commentary: Experimental Drug Access Wars Continue

CenterWatch Commentary: Experimental Drug Access Wars Continue

August 22, 2008
CenterWatch Staff

A U.S. District judge Wednesday ordered PTC Therapeutics to supply its experimental drug to 16-year-old Jacob Gunvalson, who has Duchenne muscular dystrophy, a terminal disease for which there is no known cure.

Gunvalson’s parents brought a lawsuit against PTC Therapeutics because they claim that the company had promised them that he could participate in a 96-week clinical trial of PTC 124, even though Jacob was not able to participate in the 28-day preliminary phase of the clinical trial due to exclusion criteria. The company claims no such promise was made.

What seems to have hurt PTC Therapeutics’ case was the company’s particularly close relationship with the family. The Gunvalsons claim that PTC employees made promises to the family and that a senior vice president once hosted them at her house overnight. “They had a special relationship that this court considers more than typical,” the judge said.

Although PTC president and chief executive Stuart Peltz denied there was anything unusual about the company’s relationship with the Gunvalson family, this situation should serve as a lesson to all in the industry.

You cannot form the kind of relationship with a patient where an overnight is normal while still maintaining the line between company and potential clinical trial participant. If nothing else, PTC Therapeutics blurred the line between friendship and a business relationship. And it’s not surprising that, during the many hours the Gunvalsons spent with PTC representatives, the family was led to believe their son could participate in a PTC Therapeutics clinical trial.

In a statement, Peltz said, “In contrast to big pharmaceutical concerns, it is quite natural for our team to form close relationships with patients and other members of the rare disease community.”

Do all small pharma and biotechs studying orphan diseases form these kinds of close relationships? It’s one thing to be invested in a trial’s participants and know them all by name, but it’s another to host sleepovers. PTC crossed a line and opened itself up to misinterpretations and even liability.

What if, for example, a family has reservations about their child’s participation in a clinical trial and only agrees to participate after developing a “close relationship” with the drug company’s representatives? If something goes wrong during that clinical trial, could the family claim that they did not give a truly informed consent? 

Even though I side with PTC in regard to limiting drug access, it’s easy to understand why the Gunvalsons would assume that Jacob would have access. They spent time together; they were hosted by company executives overnight; they were friends.

People who form close relationships with each other have expectations. One is that the other party will help you when you are in need.

This judgment will most certainly be overturned, but in the meantime, small biopharma companies should draw a bright line between their clinical trial participants and friends.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing